ArticleThe Journal of antimicrobial chemotherapy2026
Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
Abstract
BACKGROUND AND
objectiveWith the redefinition of the EUCAST 'I' susceptibility category, from 'intermediate' to 'susceptible, increased exposure', the focus is now to use higher doses to treat infections of this category. These higher dosages in adults provided by EUCAST are fixed, yet it is uncertain whether a similar increase should apply to paediatric doses. We aimed to compare antibiotic exposure in adults and children, using pragmatic physiologically based pharmacokinetic (PBPK) modelling and simulation to evaluate the need for dose increases in children for the 'I' susceptibility category micro-organisms.
methodsFor amoxicillin, ceftazidime, cefuroxime and ciprofloxacin, we used existing PBPK models and verified them with published adult and paediatric pharmacokinetic data. Then, the adult EUCAST category 'I' doses and a wide paediatric dosage range was simulated. We compared AUC values as a surrogate for antibiotic exposure. In addition, simulations were performed to assess the PTA of the adult and paediatric doses for specific drug-micro-organism combinations.
resultsModel verification proved successful for all antibiotics. Simulations showed that antibiotic plasma exposure increases with decreasing age using current paediatric doses. Simulating doses for neonates and infants resulted in substantially higher AUCs compared with adults receiving the EUCAST 'I' dose. Simulations showed that PTA is highly variable with age and can be poor in case of less susceptible micro-organisms.
conclusionsIn contrast to adults, there is no need to increase the currently recommended paediatric dosages for the tested antibiotics. At the same time, further simulations showed that the PTA varies by drug-micro-organism combination and age, providing a potential opportunity to tailor doses to individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.